Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Recent News

Neoadjuvant Cemiplimab-rwlc Treatment of Cutaneous Squamous Cell Carcinoma
ASTRO 2022: Use of HDR Brachytherapy for Non-Melanoma Skin Cancers of the Face
ASTRO 2022: Use of Diffusing Alpha-Emitter Radiation Therapy for Cutaneous Cancers
Use of Vismodegib in Advanced Basal Cell Carcinoma: Findings From a Multicenter Cohort Study
Adjuvant Nivolumab in Resected Merkel Cell Carcinoma: Interim Results From Phase II Trial
ASCO Quality 2022: Survey of Providers of Multidisciplinary Care in Cutaneous Squamous Cell Carcinoma
ESMO 2022: Combination Therapy With Nivolumab and Ipilimumab for Advanced Merkel Cell Carcinoma
Predicting the Future Global Disease Burden From Non-Melanoma Skin Cancer
Consensus-Based Guidelines: New European Take on Merkel Cell Carcinoma
Immunotherapy for Skin Cancer: Predicting Who Is Likely to Benefit Most
Mohs Surgery for Skin Cancer: Impact of Insurance Type on Tumor Diameters
Immunotherapy for Skin Cancer: Knowledge Gap Revealed in Survey of Dermatologists
Skin Cancer Risk in Patients With Tuberous Sclerosis
Exploring Noninvasive Imaging Techniques to Enhance Early Skin Cancer Diagnostics
Skin Cancer and Cardiac Devices: Battery-Powered Electrocautery and Curettage Versus Electrodessication and Curettage
COVID-19 and Skin Cancer: Restructuring Medical Service of UK Tertiary Center
Microcystic Adnexal Carcinoma: Upregulated Genes May Offer Diagnostic and Therapeutic Insights
Risk Factors of Skin Cancer in Older Individuals: Population-Based Study From Finland
Use of Thiazide Diuretics and Risk of Skin Cancer
Eccrine Porocarcinoma on the Face: Clinical Awareness Needed for Rare Skin Cancer
Could ctDNA Prove to Be a Biomarker in Merkel Cell Carcinoma?
Comparing Topical Ascorbic Acid Solution and Imiquimod in Treatment of Basal Cell Carcinoma
Cemiplimab-rwlc in Squamous Cell Carcinoma of the Skin: Living in the Real World
ASCO 2022: PD-1 Inhibitory–Refractory Merkel Cell Carcinoma: Is T-Cell Therapy a Step in the Right Direction?
ASCO 2022: First-in-Human Study of RM-1995 Photoimmunotherapy in Advanced Squamous Cell Skin Cancer
ASCO 2022: Pan-Canadian Merkel Cell Collaborative Provides Insight on Biopsy Decisions
ASCO 2022: Adjuvant Cemiplimab-rwlc Under Study in High-Risk Cutaneous Squamous Cell Carcinoma
Use of Navtemadlin After Failure of Immunotherapy in Merkel Cell Carcinoma
ASCO 2022: Immunotherapy Followed by Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
ASCO 2022: Oncolytic Virus Plus Cemiplimab-rwlc Under Study in Cutaneous Squamous Cell Cancer
ASCO 2022: Does Dosing Frequency and Duration of Anti–PD-1 Therapy Impact Outcomes in Skin Cancers?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.